Trifluridine/Tipiracil and Talazoparib for Advanced Colorectal or Gastroesophageal Cancer
Phase 1
45
about 5.8 years
18+
1 site in NY
What this study is about
This trial is testing the safety and best dose of talazoparib when combined with trifluridine/tipiracil in people with advanced colorectal or gastroesophageal cancer. The goal is to determine how these drugs work together to stop tumor growth.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Talazoparib Tosylate
- 2.Take Trifluridine and Tipiracil Hydrochloride
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Antineoplastic Agent [TC] (Poly(ADP-Ribose) Polymerase Inhibitors), Antineoplastic Agent [TC] (Thymidine Phosphorylase Inhibitors), trifluridine
oral, ocular (Ophthalmic Solution)
Primary: Incidence of Adverse Events, Maximum tolerated dose/ recommended phase II dose
Secondary: CEA response rate (colorectal cancer patients), Overall Response Rate (ORR), Overall Survival (OS), Plasma Concentration (Cmax), Progression Free Survival (PFS), Progressive Disease Assessment (PD)
Gastroenterology, Oncology